Ergotamine Tartrate + Caffeine Tablets

  • Migraine and headache

Ergotamine Tartrate + Caffeine Tablets Generic Name & Formulations

General Description

Ergotamine tartrate 1mg, caffeine 100mg; tabs.

Pharmacological Class

Ergot alkaloid.

How Supplied

Contact supplier.


Store at 20°-25°C (68°-77°F).

Ergotamine Tartrate + Caffeine Tablets Indications


Migraine, migraine variants, cluster headaches.

Ergotamine Tartrate + Caffeine Tablets Dosage and Administration


2 tablets at onset of attack, then 1 tablet every ½ hour if needed; max 6 tabs/attack, 10 tabs/week.


Not recommended.

Ergotamine Tartrate + Caffeine Tablets Contraindications


Peripheral vascular disease. Coronary heart disease. Hypertension. Hepatic or renal dysfunction. Sepsis. Concomitant potent CYP3A4 inhibitors (eg, ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) or other vasoconstrictors. Pregnancy. Labor and delivery.

Ergotamine Tartrate + Caffeine Tablets Boxed Warnings

Boxed Warning

Peripheral ischemia following coadministration with strong CYP3A4 inhibitors.

Ergotamine Tartrate + Caffeine Tablets Warnings/Precautions


Monitor for ergotism; do not exceed recommended dose. Nursing mothers: not recommended.



  • Manifested by intense arterial vasoconstriction, producing signs and symptoms of peripheral vascular ischemia.
  • Most cases have been associated with overdosage, though some have involved hypersensitivity.
  • Headache intermittent claudication, muscle pain, numbness, coldness and pallor of the digits may develop with chronic intoxication of ergot derivatives.
  • Do not exceed recommended dosages with long-term use.

Pregnancy Considerations

Contraindicated in pregnancy due to oxytocic effects of ergotamine.

Contraindicated during labor and delivery due to its oxytocic effect which is maximal in the third trimester.

Nursing Mother Considerations

Ergotamine is excreted in the breast milk and may cause vomiting, diarrhea, weak pulse, and unstable blood pressure in nursing infants. A decision should be made to either discontinue nursing or discontinue the drug.

Pediatric Considerations

Safety and effectiveness in pediatric patients have not been established.

Other Considerations for Specific Populations

There have been reports of drug abuse and psychological dependence in patients on ergotamine tartrate and caffeine therapy.

Ergotamine Tartrate + Caffeine Tablets Pharmacokinetics




Fecal (ergotamine), renal (caffeine). Half-life: 2 hours (ergotamine).

Ergotamine Tartrate + Caffeine Tablets Interactions


See Contraindications. Potentiated by CYP3A4 inhibitors (eg, protease inhibitors, macrolides, azole antifungals, saquinavir, nefazodone, fluoxetine, fluvoxamine, grapefruit juice, zileuton), propranolol, nicotine. Severe hypertension with sympathomimetics.

Ergotamine Tartrate + Caffeine Tablets Adverse Reactions

Adverse Reactions

Vasoconstrictive complications or ergotism (eg, ischemia, cold extremities, vasospasm, ECG changes, hyper- or hypotension, numbness, gangrene, dizziness), precordial or muscle pain, tachycardia, bradycardia, nausea, vomiting, local edema, itching; rarely: retroperitoneal and pleuropulmonary fibrosis, cardiac valve fibrosis (chronic use).

Ergotamine Tartrate + Caffeine Tablets Clinical Trials

See Literature

Ergotamine Tartrate + Caffeine Tablets Note


Formerly known under the brand names Cafergot, Migergot.

Ergotamine Tartrate + Caffeine Tablets Patient Counseling

Patient Counseling

Do not exceed the dosing guidelines.

Use only to treat migraine headaches; ergotamine/caffeine is not effective for other types of headaches and the product lacks analgesic properties.

Numbness or tingling in the fingers and toes, muscle pain in the arms and legs, weakness in the legs, pain in the chest or temporary speeding or slowing of the heart rate, swelling or itching: Report immediately.